摘要
目的:评价普拉克索治疗帕金森病(PD)伴抑郁的临床疗效。方法:采用随机对照研究,将68例PD伴抑郁患者随机分为对照组、帕罗西汀组和普拉克素组。治疗12周后评价其疗效,评价指标包括Hamilton抑郁量表(HAM-D)、Zung抑郁自评量表和统一帕金森病评分量表(UPDRS),观察各量表评分相对于基线值的变化情况。结果:普拉克索组HAM-D和Zung总评分第4周时与基线值相比已有下降趋势,而在第8周时与对照组相比差异有统计学意义(P<0.05),其作用与帕罗西汀组相比差异无统计学意义(P>0.05),而UPDRS评分均差异无统计学意义(P>0.05)。结果:普拉克索具有抗抑郁作用,可能在治疗后4～8周时开始发挥比较明显的抗抑郁作用,治疗8周时其抗抑郁作用强度似乎接近于帕罗西汀,抗抑郁作用可能不依赖于其对于运动症状的改善。
Aim： To assess the anti-depression effect of pramipexole in Parkinson＇ s disease with depression. Methods： 68 Parkinson＇ s disease patients with depression, without history of motor fluctuations and/or dyskinesia, were enrolled and randomly divided into three groups including the control group, paroxetine group, and pramipexole group, which accordingly received no antidepressant drugs, paroxetine or pramipexole. Through 12 weeks of treatment, all the patients were evaluated by Hamilton Rating Scale for Depression （HAM-D）, Zung self-rating depressive scale （SDS）, UPDRS Scale. The changes were observed from the baseline to the 4th week, the 8th week and the 12th week. Results： In the pramipexole group, the total score means of HAM-D and Zung self-rating scale had significant improvement trends at the end of the 4th week. While at the end of the 8th week, there was statistically difference between the pramipexole group and the control（P〈0.05）, but no statistically difference between the pramipexole group and the paroxetine group（P〉 0.05）. The changes of UPDRS subscore means,// and m, showed no statistically difference （P〉0.05）. Conclusion： Pramipexole has anti-depression effect, which reveals obviously after 4 to 8 weeks of the treatment. The anti-depression effect of pramipexole is possiblely independent of the treatment-related motor improvement, and the effect may be close to that of paroxetine after 8 weeks of the treatment.
出处
《中国临床神经科学》
2010年第2期188-194,共7页
Chinese Journal of Clinical Neurosciences
